Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S-531011 plus fruquintinib ± pembrolizumab in MSS/pMMR metastatic colorectal cancer
jRCT2031260047Phase 2Recruiting
- Sponsor
- Shionogi & Co., Ltd.
- Start
- May 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of S-531011, fruquintinib and pembrolizumab in colorectal adenocarcinoma (2 arms), sponsored by Shionogi & Co., Ltd. Primary endpoints: Dose-Limiting Toxicity (DLT) Rate and Objective Response Rate (ORR). Started May 2026; status: recruiting.
02
Drugs
03
Conditions
colorectal adenocarcinoma
Beyond the preview
Go deeper on jRCT2031260047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260047.